Oncolytic Gene Therapy Combined with Double Suicide Genes for Human Bile Duct Cancer in Nude Mouse Models

Journal of Surgical Research

Volumn 157, Issue 1, 2009, Pages

  Kojima, Yoh ^a   Honda, Kazuo ^a   Hamada, Hirofumi ^b   Kobayashi, Nobuaki ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

adenovector; E1B deletion; HSV tk; HuCCT1 cells; nude mice; UPRT

Indexed keywords

ADENOVIRUS VECTOR; FLUOROURACIL; GANCICLOVIR; THYMIDINE KINASE; URACIL PHOSPHORIBOSYLTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BILE DUCT CARCINOMA; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; SUBCUTANEOUS TISSUE TUMOR; SUICIDE GENE THERAPY;

ADENOVIRIDAE; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTIVIRAL AGENTS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CELL LINE, TUMOR; CHOLANGIOCARCINOMA; COMBINED MODALITY THERAPY; FEMALE; FIBROBLASTS; FLUOROURACIL; GANCICLOVIR; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; HERPES SIMPLEX; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70349843885     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2008.12.016     Document Type: Article

References (18)

1. Uehara T., Honda K., Hatano E., et al. Gene transfer to the rat biliary tract with the HVJ-cationic liposome method. J Hepatol 30 (1999) 836
2. Terao R., Honda K., Hatano E., et al. Suppression of proliferative cholangitis in a rat model with direct adenovirus-mediated retinoblastoma gene transfer to the biliary tract. Hepatology 28 (1998) 605
3. Kojima Y., Honda K., Kotegawa H., et al. Adenovirus-mediated p53 gene transfer to the bile duct by direct administration into the bile in a rat cholangitis model. J Sug Res 128 (2005) 126
4. Vaha-Koskela M.J., Heikkila J.E., and Hinkkanen A.E. Oncolytic viruses in cancer therapy. Cancer Lett 254 (2007) 178
5. Khan S.A., Thomas H.C., Tolodano M.B., et al. p53 mutations in human cholangiocarcinoma: A review. Liver Int 25 (2005) 704
6. Heise C., Sampson-Johannes A., Williams A., et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 3 (1997) 639
7. Borrelli E., Heyman R., His M., et al. Targeting of an inducible toxic phenotype in animal cell. Proc Natl Acad Sci USA 85 (1988) 7572
8. Kanai F., Kawakami T., Hamada H., et al. Adenovirus-mediated transduction of Esherichia coli uracil phosphoribosyltransferase gene sensitizes cancer cells to low concentrations of 5-fluorouracil. Cancer Res 58 (1998) 1946
9. Mani S., Sciortino D., Samuels B., et al. Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma. Invest New Drugs 17 (1999) 97
10. Furuse J., Okusaka T., Funakoshi A., et al. Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer. Jpn J Clin Oncol 36 (2006) 552
11. Yonemoto N., Furuse J., Okusaka T., et al. A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. Jpn J Clin Oncol 37 (2007) 843
12. Shimizu T., Shimada H., Ochiai T., et al. Enhanced growth suppression in esophageal carcinoma cells using adenovirus-mediated fusion gene transfer (uracil phosphoribosyl transferase and helpes simplex virus thymidine kinase). Cancer Gene Ther 8 (2001) 512
13. Schneider J.F., Fisher F., Goding C.R., et al. Mutational analysis of the adenovirus E1a gene: the role of transcriptional regulation in transformation. EMBO J 6 (1987) 2053
14. Takahashi M., Sato T., Sagawa T., et al. E1B-55K-deleted adenovirus expressing E1A-13S by AFP-enhancer/promoter is capable of highly specific replication in AFP-producing hepatocellular carcinoma and eradication of established tumor. Mol Ther 5 (2002) 627
15. Sirica A.E., Zhan Z., Lai G.H., et al. A novel "patient-like" model of cholangiocarcinoma progression based on bile duct inoculation of tumorigenic rat cholangiocyte cell lines. Hepatology 47 (2008) 1178
16. Lie-A-Ling M., Bakker C.T., Deurholt T., et al. Selection of tumor specific promoters for adenoviral gene therapy of cholangiocarcinoma. J Hepatol 44 (2006) 126
17. Tullo A., D'Erchia A.M., Honda K., et al. New p53 mutation in hilar cholangiocarcinoma. Eur J Clin Invest 30 (2000) 798
18. Strum PD, Baas IO, Clement MJ, et al. Alterations of the p53 tumor-suppressor gene and K-ras oncogene in perihilar cholangiocarcinoma from a high-incidence area. Int J Cancer 9;78:695.